Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
60 hedge funds and large institutions have $37.5M invested in Clearside Biomedical in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 21 reducing their positions, and 16 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.53% less ownership
Funds ownership: 2.35% → 1.81% (-0.53%)
10% less funds holding
Funds holding: 67 → 60 (-7)
19% less call options, than puts
Call options by funds: $470K | Put options by funds: $579K
33% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 21
35% less capital invested
Capital invested by funds: $57.8M → $37.5M (-$20.3M)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.38M |
| 2 |
Renaissance Technologies
New York
|
+$869K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$822K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$232K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$10.5M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.44M |
| 3 |
Two Sigma Investments
New York
|
-$1.21M |
| 4 |
Morgan Stanley
New York
|
-$927K |
| 5 |
Two Sigma Advisers
New York
|
-$442K |
CLSD Hedge Fund Activity: Q1 2022 in Review
60 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2022, worth a combined $37.5M — down 35% from $57.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CLSD and 9 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 14 added.
The largest buyer was Millennium Management, adding an estimated $1.38M. The largest seller was RTW Investments, exiting entirely with an estimated $10.5M sold.
- 60 institutional investors held Clearside Biomedical (CLSD) as of Q1 2022, down from 67 in Q4 2021.
- Funds reported $37.5M of Clearside Biomedical stock for Q1 2022, down 35% quarter-over-quarter.
- 9 funds opened new Clearside Biomedical positions in Q1 2022 and 16 closed out, a net change of -7 holders.
- The largest Clearside Biomedical buyer in Q1 2022 was Millennium Management, an estimated $1.38M added.
- The largest Clearside Biomedical seller in Q1 2022 was RTW Investments, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2022.